News | May 06, 2011

African Americans Experience Worse Long-Term Outcomes After PCI

May 6, 2011 – African American patients who undergo angioplasty and stenting fare worse over the long run than patients of other races, regardless of socioeconomic status. In fact, the risk of dying within about three years is more than twice as high among African Americans, according to a study presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions.

“We need to channel healthcare resources to effectively treat this vulnerable population,” said Steve Attanasio, D.O., an interventional cardiology fellow at Rush University Medical Center in Chicago. “It’s very worrisome that the first major cardiac problem many of these patients experience following coronary intervention is death.”

The study focused on 1,432 consecutive patients who had percutaneous coronary intervention (PCI) at John H. Stroger, Jr. Hospital of Cook County in Chicago and received follow-up within the same public health system. The patients were relatively young (57-years-old on average). They were also relatively high-risk: Only about 30 percent had a pre-scheduled procedure for stable coronary disease, while the remaining 70 percent needed urgent PCI because of a heart attack or unstable chest pain.

After an average follow-up of 2.7 years, the combined rate of survival without heart attack or need for a repeat procedure in the treated artery was 78 percent among African American patients, as compared with 86 percent among patients of another race (p=0.001). The overall death rate at 2.7 years was 8.6 percent; however, among African Americans, it spiked to 12.1 percent, as compared with 5 percent among other patients (p

The reason for the increased risk among African Americans is not yet known, though many things may play a role, including poorly understood genetic and sociocultural factors. But the importance of aggressively treating risk factors such as diabetes, high blood pressure, high cholesterol and smoking is clear, as is the need to educate patients about a heart-healthy lifestyle.

“The ultimate goal is prevention,” Attanasio said. “We need to reach out not only to patients but also to healthcare providers. It’s not enough to perform a stenting procedure. These patients require close follow-up.”

This study received no outside funding.

For more information:,

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init